Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

6.63
+0.13002.00%
Post-market: 6.690.0600+0.90%19:32 EDT
Volume:519.21K
Turnover:3.44M
Market Cap:528.03M
PE:-9.23
High:6.82
Open:6.56
Low:6.40
Close:6.50
52wk High:6.82
52wk Low:0.9807
Shares:79.64M
Float Shares:4.56M
Volume Ratio:0.67
T/O Rate:11.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7183
EPS(LYR):-1.2929
ROE:-57.73%
ROA:-27.15%
PB:3.95
PE(LYR):-5.13

Loading ...

Prelude Therapeutics Stock Rises on Narrower 2Q Loss, Plans to Start Trial for Breast Cancer Drug

Dow Jones
·
Aug 21

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Aug 19

Ovid Therapeutics Q2 Revenue Beats Estimates

Reuters
·
Aug 13

Prelude Therapeutics Incorporated Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Cardiff Oncology Q2 Operating Expenses Fall on Lower R&D Costs

Reuters
·
Aug 12

Bolt Biotherapeutics Q2 Net Loss Narrows on Restructuring and Lower Research Activity

Reuters
·
Aug 12

Prelude Therapeutics Q2 EPS $(0.14) Beats $(0.20) Estimate, Sales $5.704M

Benzinga Earnings
·
Aug 11

Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)

TIPRANKS
·
Aug 11

Prelude Therapeutics Q2 Revenue USD 5.704 Million

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Q2 EPS USD -0.14

THOMSON REUTERS
·
Aug 11

Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire
·
Aug 11

Prelude Therapeutics Incorporated Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Aug 10

Prelude Therapeutics Price Target Maintained with a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Jul 29

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

TIPRANKS
·
Jul 28

Prelude Therapeutics Shareholders Back Leadership and Governance

TIPRANKS
·
Jun 11

Prelude Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 11

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
May 15

Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 14

Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

TIPRANKS
·
May 12